Investment Rating - The report maintains a "Buy" rating for WuXi Biologics (2269 HK) with a target price raised to HKD 50.10 [4][6]. Core Insights - The company is expected to achieve rapid growth from 2025 to 2027, with a projected revenue increase of 16.7% to RMB 21.79 billion in 2025, and a significant net profit growth of 46.3% to RMB 4.91 billion [1][4]. - The ability to secure new orders is improving, with a record 209 new projects expected in 2025, half of which are from the U.S. market, indicating a recovery in the Chinese business as well [2][4]. - The demand for services in the dual antibody and antibody-drug conjugate (ADC) sectors is increasing, with these projects making up two-thirds of ongoing projects, suggesting a strong future market demand [3][4]. Financial Summary - Revenue projections for 2025-2027 have been adjusted upwards by 2.3%, 3.2%, and 4.0% respectively, while net profit estimates have been increased by 2.0%, 13.5%, and 14.0% [4][5]. - Key financial metrics for 2025 include total revenue of RMB 21.79 billion, gross profit margin improvement of approximately 5 percentage points, and Non-IFRS adjusted net profit of RMB 65.9 billion, reflecting a 22.0% year-on-year increase [1][5]. - The company’s earnings per share (EPS) for 2025 is projected at RMB 1.20, with a price-to-earnings (P/E) ratio of 30.4 [5][6].